The future of dermatology depends on the continued development of breakthrough technologies that improve patient care. From aesthetics to medical dermatology, the field has seen an acceleration of progress driven by new therapeutics, diagnostics, and health information technologies. The successful management of psoriasis with biologics has augmented our ability to achieve skin clearance in millions. Dermatology stands at the forefront of immunotherapy and gene therapy with demonstration of the feasibility of using chimeric antigen receptor T cells for pemphigus vulgaris1 and promising phase 1 trial results for a genetically corrected autologous epidermal graft in recessive dystrophic epidermolysis bullosa.2 Prior to the advent of immunotherapy, metastatic melanoma was largely considered a death sentence. With the approval of ipilimumab (2011), pembrolizumab (2014), and nivolumab (2014), patients with advanced melanoma are living longer, with some having durable responses. In aesthetics, dermatologist-led innovation has driven growth in noninvasive procedures (eg, cryolipolysis, fractional ablative resurfacing) that have improved patient quality of life.3 In addition, the first US Food and Drug Administration (FDA)-approved systemic therapy for moderate-to-severe atopic dermatitis rightfully deserves its FDA breakthrough therapeutic designation. Finally, dermatology is leading the telemedicine revolution by providing an opportunity for patients to obtain greater access with lower costs to specialty care.
Xu S, Breslin J, Ju W. Catalyzing Future Drug, Device, and Information Technology Breakthroughs in DermatologyAnnouncing Advancing Innovation in Dermatology’s Accelerator Fund. JAMA Dermatol. Published online April 11, 2018. doi:10.1001/jamadermatol.2018.0590
Customize your JAMA Network experience by selecting one or more topics from the list below.